Christina Caon

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi Maximising therapeutic outcomes in patients failing on current therapy
    Christina Caon
    Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S33-6. 2009
  2. ncbi Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data
    Christina Caon
    Multiple Sclerosis Center at Wayne State University School of Medicine, Detroit, MI, USA
    J Neurosci Nurs 42:S5-9. 2010
  3. ncbi Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
  4. ncbi Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
  5. ncbi Acute transverse myelitis with normal brain MRI : long-term risk of MS
    Jui Perumal
    Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    J Neurol 255:89-93. 2008
  6. ncbi Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
    Aaron Boster
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Arch Neurol 66:593-9. 2009
  7. ncbi Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
  8. ncbi Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
  9. ncbi Pediatric-onset multiple sclerosis in African-American black and European-origin white patients
    Aaron L Boster
    Department of Neurology, The Ohio State University, Columbus, Ohio, USA
    Pediatr Neurol 40:31-3. 2009

Collaborators

  • Omar Khan
  • Jiani Hu
  • Kenneth L Tyler
  • Carol Saunders
  • Jennifer Smrtka
  • Aaron L Boster
  • Aaron Boster
  • Fen Bao
  • Imad Zak
  • Alexandros Tselis
  • Jui Perumal
  • Jai Perumal
  • Joseph R Berger
  • Stephanie Hreha
  • Stephanie A Hreha
  • Jose Vazquez
  • Scott Millis
  • Christina F Endress
  • Jai S Perumal
  • Christina Endress
  • Ramya Penmesta
  • Michael K Racke
  • Zahid Latif
  • Megan MacKenzie
  • Robert Lisak
  • Rana Zabad

Detail Information

Publications9

  1. ncbi Maximising therapeutic outcomes in patients failing on current therapy
    Christina Caon
    Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S33-6. 2009
    ..Formal switching algorithms need to be developed in order to ensure that all patients who could benefit from such an approach are managed in a timely and optimal manner...
  2. ncbi Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data
    Christina Caon
    Multiple Sclerosis Center at Wayne State University School of Medicine, Detroit, MI, USA
    J Neurosci Nurs 42:S5-9. 2010
    ..Nursing interventions that can improve adherence, including telephone counseling and motivational interview techniques, are also addressed...
  3. ncbi Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
    ..These data support the long-term effect of GA on maintaining axonal metabolic function and protection from sublethal injury as well as the feasibility of employing brain (1)H-MRS in long-term investigative studies in MS...
  4. ncbi Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
    ..To compare the long-term effect of disease-modifying therapies (DMT) on brain volume loss in relapsing-remitting MS (RRMS) patients...
  5. ncbi Acute transverse myelitis with normal brain MRI : long-term risk of MS
    Jui Perumal
    Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    J Neurol 255:89-93. 2008
    ..To investigate the long-term risk of developing MS in patients presenting with acute transverse myelitis (ATM) and normal brain MRI scans at onset...
  6. ncbi Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
    Aaron Boster
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Arch Neurol 66:593-9. 2009
    ..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)...
  7. ncbi Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
    ..These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA...
  8. ncbi Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
    ..In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients...
  9. ncbi Pediatric-onset multiple sclerosis in African-American black and European-origin white patients
    Aaron L Boster
    Department of Neurology, The Ohio State University, Columbus, Ohio, USA
    Pediatr Neurol 40:31-3. 2009
    ..50; P < 0.001). These findings are consistent with data suggesting a more aggressive disease phenotype among African-American blacks with adult-onset multiple sclerosis. Larger multicenter studies are warranted to confirm the findings...